Sandoz submits biologics license application for proposed biosimilar trastuzumab to US FDA

Novartis

20 December 2021 - Biologics license application is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix.

Sandoz today announced the submission of its biologics license application for a proposed biosimilar trastuzumab (150 mg, for intravenous use) developed by EirGenix, Inc. to the US FDA.

Read Novartis press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Biosimilar , Dossier